Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.

Nature communications - 24 Aug 2023

Hiltbrunner Stefanie, Cords Lena, Kasser Sabrina, Freiberger Sandra N, Kreutzer Susanne, Toussaint Nora C, Grob Linda, Opitz Isabelle, Messerli Michael, Zoche Martin, Soltermann Alex, Rechsteiner Markus, van den Broek Maries, Bodenmiller Bernd, Curioni-Fontecedro Alessandra

Abstract excerpt

Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell lung cancer (NSCLC), however, some of the patients develop resistance following initial response. Here, we analyze the immune phenotype of matching tumor samples from a cohort of NSCLC patients showing good initial response to immune checkpoint inhibitors, followed by acquired resistance at later time points. By using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8-Positive T-Lymphocytes

Share to Immune Checkpoint Inhibitors

Share to Immunosuppressive Agents

Share to Lung Neoplasms

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 37620318
DOI: 10.1038/s41467-023-40745-5
PMCID: PMC10449840

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype.PMID 37620318Read ↗

Acquired resistance to anti-PD1 therapy in patients with NSCLC reveals changes in T cell phenotypes and <i>MET</i> amplificationSemantic proximity Read ↗

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerSemantic proximity Read ↗

High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLC.Semantic proximity Read ↗

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerSemantic proximity Read ↗

A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancerSemantic proximity Read ↗

Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapySemantic proximity Read ↗

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancerSemantic proximity Read ↗

Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance.Semantic proximity Read ↗

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.Semantic proximity Read ↗

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity Read ↗

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.